News

April 14, 2026

Cellphire Therapeutics Highlights New Preclinical Data Demonstrating Vascular Repair and Neuroprotective Effects of Platelet-Derived Biologic in Traumatic Brain Injury

Cellphire Therapeutics, Inc. reported new preclinical data in Blood showing its freeze-dried platelet-derived biologic improves vascular stability and promotes blood-brain barrier repair in traumatic brain injury. The findings, generated with University of California, San Francisco, highlight potential to reduce hemorrhage and inflammation, expanding platelet-based therapies beyond hemostasis.

April 6, 2026

Cellphire Therapeutics Expands Issued Core Technology Patents

Cellphire Therapeutics, Inc. announced the issuance of six U.S. patents in 2025 covering its stabilized platelet technologies, including CLPH-211 and CLPH-511.

October 1, 2025

Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results

The CRYPTICS study was a Phase 2/3 adaptive design study, titled “Randomized Controlled Trial Comparing Dimethyl Sulfoxide Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery” (CRYPTICS - NCT04709705) that investigated the use of CLPH-511 in acute hemorrhage.

April 28, 2025

Cellphire Therapeutics Welcomes Randall Stanicky to its Board of Directors

April 22, 2025

CRYPTICS Phase 2/3 Clinical Study stopped early for efficacy following pre-planned interim analysis by Independent Data Monitoring Committee (IDMC)

March 11, 2025

Cellphire Therapeutics CLPH-511 Fast Track Designation Granted!

FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply!

February 18, 2025

Cellphire Therapeutics Reaches Interim Analysis Milestone of 150 Patients in Phase 2/3 CRYPTICS Clinical Study

Cellphire Therapeutics has completed enrollment of 150 subjects in its CRYPTICS clinical trial, triggering an interim analysis to evaluate the safety and efficacy of its investigational cryopreserved platelet product, CLPH-511, for uncontrolled bleeding in cardiopulmonary bypass surgery. This milestone brings the company closer to offering a platelet alternative with extended shelf life, potentially improving access to critical care.

August 5, 2024

Cellphire Therapeutics announces the addition of Dr. Damien Bates as Chief Medical Officer and transition of Allan Alexander, our current CMO to an advisory role.

We are excited to announce that Damien Bates, MD, PhD, FRACS, MBA joined the company as Chief Medical Officer.